Latest News

  • Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab Read More
  • Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders Read More
  • Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference Read More

Investors

Working at Alkermes